Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Argenx Se (ARGX – Research Report) on May 10 and set a price target of $485.00. The company’s shares closed last Friday at $374.63.
According to TipRanks, Thompson CFA is a 4-star analyst with an average return of 13.8% and a 45.28% success rate. Thompson CFA covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Argenx Se, and Dianthus Therapeutics.
In addition to Stifel Nicolaus, Argenx Se also received a Buy from JMP Securities’s Jason Butler in a report issued on May 10. However, on the same day, UBS maintained a Hold rating on Argenx Se (NASDAQ: ARGX).
ARGX market cap is currently $22.3B and has a P/E ratio of -72.48.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Argenx Se (ARGX) Company Description:
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
Read More on ARGX:
